The Life Sciences team advised TransCode Therapeutics, Inc. (Nasdaq: RNAZ) on its registered direct offering of an aggregate of 2,000,000 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $3.50 per share and accompanying warrants. Each share of common stock was offered together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $3.25 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $3.25 per share. The Series A-1 warrants and Series A-2 warrants are exercisable immediately and expire three years and five years, respectively, from the date of issuance. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $7.0 million. The offering closed on June 9, 2023.
TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics.
For more details, read the press release.